Evidence map›Paper›PMID 40542274›Full record

ArticleJournal of cancer research and clinical oncology2025

Autophagy-related biological targets and network mechanisms of juglone against bladder cancer.

Yuanfeng Zhang, Enguang Yang, Xinyu Zhang, Ze Zhang, Guoxin Huang, Baoyuan Tang, Chaohu Chen, Longhui Lai, Zixu Pei, Yonghai Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuanfeng ZhangInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Gansu, 730000, Lanzhou, P.R. China.
Enguang YangInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Gansu, 730000, Lanzhou, P.R. China.
Xinyu ZhangInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Gansu, 730000, Lanzhou, P.R. China.
Ze ZhangInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Gansu, 730000, Lanzhou, P.R. China.
Guoxin HuangClinical Research Center, Shantou Central Hospital, 515031, Shantou, P.R. China.
Baoyuan TangThe Second Clinical Medical School, Lanzhou University, Gansu, 730000, Lanzhou, P.R. China.
Chaohu ChenInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Gansu, 730000, Lanzhou, P.R. China.
Longhui LaiInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Gansu, 730000, Lanzhou, P.R. China.
Zixu PeiAndrology Center, Department of Urology, Peking University First Hospital, Peking University, 100034, Beijing, P.R. China.
Yonghai ZhangDepartment of Urology, Shantou Central Hospital, Shantou Key Laboratory of Basic and Translational Research of Malignant Tumor, Guangdong, 515031, Shantou, P.R. China.
Zhiping WangInstitute of Urology, Gansu Province Clinical Research Center for Urinary System Disease, The Second Hospital & Clinical Medical School, Lanzhou University, Gansu, 730000, Lanzhou, P.R. China. wangzplzu@163.com.

Funding

Guangdong Basic and Applied Basic Research Foundation 2023A1515220184Guangdong Basic and Applied Basic Research Foundation 2023A1515220213Key Research and Development Program of Gansu Province 23YFFA0007Major Program of Gansu Province 24ZDFA002National Natural Science Foundation of China 82372685
6 · The paper itself

Abstract

objectiveThis study aimed to explore juglone's mechanism in inducing autophagy and apoptosis in bladder cancer (BLCA) via network pharmacology and experimental validation.

methodsJuglone's effects on BLCA cell proliferation, apoptosis, and autophagy were assessed using CCK-8, flow cytometry, transmission electron microscopy, and Western blotting. Network pharmacology, molecular docking, and dynamics simulations identified key targets. In vivo validation employed H&E, immunohistochemical, and TUNEL staining.

resultsJuglone suppressed T24 and UMUC-3 cell proliferation, enhanced autophagy markers, and induced apoptosis. Network analysis identified 108 shared targets, with AKT1, CASP3, and TP53 as core nodes. Pathway enrichment implicated the PI3K/Akt signalling pathway, supported by molecular docking. Autophagy inhibition reduced juglone-induced apoptosis, confirming autophagic death's role.

conclusionsJuglone triggers BLCA autophagy via PI3K/AKT/mTOR, upregulates apoptotic proteins, and activates caspase 3, promoting apoptosis.

Indexed as

AutophagyNaphthoquinonesUrinary Bladder NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationHumansMiceMice, NudeMolecular Docking SimulationNetwork PharmacologyPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionXenograft Model Antitumor AssaysjugloneNaphthoquinonesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktAutophagyBladder cancerJugloneNetwork pharmacologyPI3K/AKT pathway

Identifiers

PMID40542274
PMCPMC12181109

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.